BSEBIOGEN PHARMACHEM INDUSTRIES L· FinanceHighNeutral
Announced Wed, 5 Aug, 2026 · 15:43 IST

Q1 FY27 results: revenue drops 71 percent, profit falls sharply

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.4%Reaction day
₹0.29
prior close
₹0.29
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-3.8% vs market
Other Financial Services peers, median of 84sector+0.0%-3.4% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.4 pts less than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+3.4
15m
+3.4
30m
-3.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.4+0.4-3.8+0.0-3.4
Next day
+0.0+0.4-0.4+0.0+0.0
2d
+3.4+0.3+3.1+0.0+3.4
3d
-3.4+0.2-3.6+0.0-3.4
4d
-3.4+0.5-4.0-0.3-3.1
5d
-3.4+0.7-4.1-0.6-2.9
1w
+0.0+0.9-0.9-0.6+0.6
15d
-3.4+1.6-5.1-2.1-1.4
1m
-3.4+2.4-5.8-2.0-1.4
2m
-3.4+1.1-4.6-4.0+0.6
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Other Financial Services peers, median of 84Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results for quarter ended June 30, 2026. Revenue from operations fell to Rs. 44.34 lacs from Rs. 154.28 lacs last year, a 71 percent drop. Net profit declined to Rs. 22.14 lacs from Rs. 134.48 lacs. Gross product sales were nil; only other operating income booked. Paid-up equity capital rose to Rs. 10,530.37 lacs from Rs. 9,026.03 lacs, indicating a share issuance. Auditors issued an unmodified limited review.

Likely market impact

Sharp year-on-year fall in revenue and profit signals weak quarterly performance. Recent share issuance may dilute existing shareholders.